Roivant Sciences 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Roivant reported $31 million of net revenue from Lysraia in its first 5 weeks on the market after approval in August; hundreds of patients were on paid drug at September 30, and many hundreds were on paid drug by the call.
- Management reported a net loss from continuing operations of $153 million, or $133 million on a non-GAAP basis, and cash of $4.2 billion as of 9/30.
- In the IMVT-1402 RA study, 92.5% of patients who continued on 600 milligrams retained an ACR20 response at week 28, compared with about 75% on placebo; 300 milligrams performed similarly to placebo.
- The 600-milligram arm also showed an ACR50 response in 80% of patients at week 28 versus 56% on placebo, with a nominal p-value; ACR70 results also separated from placebo without a nominal p-value.
- IMVT-1402 safety was consistent with prior reports, with event rates comparable to placebo and no new safety signals.
- Mosley reported a 56% placebo-adjusted PVR reduction at week 16 and a statistically significant 35-meter improvement in 6-minute walk at week 16 in PHLD; its Phase 3 study is screening and enrolling.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Welcome to the Roivant second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press star 11 on your telephone, and you will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. As a reminder, we ask that you please limit to one question. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Stephanie Lee.
Please go ahead. Good morning, and thanks for joining today's call to review Roivant's second quarter ended September 30th, 2026.
I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today, as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we have filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. With that, I'll turn it over to Matt.
Thanks, Steph, and thank you all for joining this morning. I'm glad you're all here. I'm going to go through the deck, and I'll announce the slide numbers as I hit them. I'll start with the agenda on slide three. Just a lot to hit today, so between stuff that we've already talked about on calls and some pretty exciting new updates. I'm not going to be able to go through it all in detail, but I just want to say what a tremendous quarter it's been for us, and obviously transformational with the commercial launch of LISRAYA, as well as some other items. I'll start on page four, which is hitting, because this is our last quarterly update in 2026. It's been a phenomenal year for us, right?
Starting out with our calendar Q1 last February with the positive data in cutaneous sarcoidosis. Then the fact that we got a trial started in LPP and in CS. We got LISRAYA approved. We got the NIU data. The sort of Brepo franchise, the Priovant team executing at incredible quality. For 1402, obviously the RA data was a really tremendous surprise, and today we're putting out the Period 2 data, which is also surprising in that we hit the primary endpoint there, which feels really, really good as far as where that drug is headed. Obviously, earlier this quarter, we also announced that we hadn't succeeded in CLE, and we're announcing today, I can talk a little more about it, but that we're not going to wind up progressing in all likelihood in Sjögren's based on various updates in the field.
We're going to run that study out and learn what we can from it. Then an amazing year for mosliciguat as well, with obviously the phenomenal data earlier this quarter in PH-ILD, as well as the starting of the phase III study there and the ongoing combo study with Tyvaso. Just an incredible year with a lot of really, really great updates. It's going to be tough to top in 2027, but we have lots of plans for that as well. I will start briefly, although I know there will be a lot of questions about it, with the commercial quarter. Obviously, in August, we got LISRAYA approved. It's a really exciting moment for us, for the dermatomyositis community, for patients, for prescribers. We're really proud that it's out on the market. This quarter reflects, on slide seven, really five weeks on the market from approval.
There's only so much you can take away from it. Obviously, $31 million of net revenue reflects strong initial demand, lots of unmet medical need, lots of physician and patient enthusiasm. Feeling really, really great about that. There were hundreds of patients on paid drug at the end of the quarter. There are many hundreds of patients on paid drug now. We have a broad initial prescriber base, and the early payer dynamics have supported good uptake, though it's a little too early to extrapolate exactly what's going to happen from here. I'm sure we'll get some questions about exactly how to think about this. We're not providing a ton of information now because it's early, but we feel great about what we're learning from the field. The initial patient and prescriber feedback is strong, although again, it's early in the launch.
One question I'm sure we'll get is on stocking or inventory dynamics. Again, we record revenue when the specialty pharmacies buy the drug from us, so there was a meaningful amount of undispensed drug as of 9/30. That drug has all been dispensed following the end of the quarter, and we continue to see strong uptake. I think it really is a reflection of the pharmacies trying to get ahead of demand. There's probably a tailwind from those dynamics in the September quarter. There'll probably be a modest headwind from those dynamics in the December quarter, and I expect inventory and stocking to be completely irrelevant as we round the corner into next year. Overall, again, just tremendously pleased with what this means in terms of patient and physician demand, in terms of execution from the Priovant team.
I think it's really just a signal of how high the unmet need has been in dermatomyositis, that so many patients and so many prescribers are working with us. The payer dynamics have been clean so far. I expect we'll start to see more of these policies coming into effect that will sort of shape that from here on out, so we'll have to watch that and learn more about it as it comes. I'd say those plans have been, some have been quite good, some have been a little bit more challenging, but I think we're going to be able to work through all of that, again, given the amount of patient and physician demand for the drug. Happy to take questions on it. Not going to talk much more about this today, but obviously we'll continue to provide updates on the commercial uptake as we go.
I want to jump now to another update that I wasn't totally expecting to provide today, but it's a great update, which is that period two of the IMVT-1402 RA study has now read out. As a reminder on slide nine of the way the study worked, this was a randomized withdrawal trial in which in period one, all patients were on 600 milligrams, that's the high dose of 1402, and we reported that data. As a reminder, we had 70% plus ACR20 responses, 50% plus, kind of mid-50s ACR50 responses, and around 35% ACR70 responses at the end of that period one. In period two, those patients who had achieved an ACR20 response were then put into a randomized withdrawal portion, where they were either kept on 600 or randomized down to 300 or placebo.
The primary endpoint was ACR20 at the end of that 12-week period, which you can sort of think of as an ACR20 maintenance endpoint, in that it's 100% of those patients roughly started or were randomized into this, had ACR20 responses. If you look at slide 10, it was 118 patients had that ACR20 response, and 117 of them were effectively re-randomized for the efficacy analysis in period two, or 118 were re-randomized, 117 were analyzed. The disposition was pretty straightforward in terms of balance across the arms. As a reminder, before we get to the actual data on slide 11, this is a big unmet medical need, right? These patients have all failed multiple lines of therapy. Many of them have failed TNFs and JAK inhibitors. Some of them have also failed IL-6s, et cetera. We think there's about 85,000 patients in the U.S.
We'll talk more about the commercial opportunity here at our upcoming investor day in December. But this is a large number of patients who have struggled to get adequately treated, and we know that autoantibody pathology matters, at least in some of these patients. It's increasingly clear that we have found a subset of patients for whom it matters quite a lot. These patients on slide 12 have significant morbidity and quality of life impairment. A significant portion of them are fully work disabled for over a decade. They have many consultations with their physicians. A large number of them are dependent on external help to live. A lot of them require surgery. A lot of them cannot walk or report walking disabilities. These are really struggling patients with late-line RA. This enrolled, the trial on 13 enrolled a difficult-to-treat population.
These were fourth-line plus patients having failed conventional therapy, and again, two-plus mechanisms of advanced therapy. You can see a little bit about the This is all from the previously reported data on slide 13. The arms on slide 14 were reasonably well-balanced once you got into the randomized withdrawal period. Similar disease severity, similar balance of prior meds, et cetera. So, a pretty well-balanced study. I think what we saw on slide 15 was just phenomenal across a couple of dimensions. So, remember, 100% of these patients approximately had an ACR20 response at the beginning of this period. Almost all of them, 92.5%, still had an ACR20 response at the end of week 28, whereas only 75% ish had an ACR20 response on placebo. Notably, that got a P-value for the 600-milligram arm.
Notably, I think this is an important finding, 300 milligrams was not enough to preserve the response. 300 milligrams looked pretty similar to placebo, which I think is just a further reinforcement of something we believed all along, which is that depth of IgG suppression really matters across FcRn indications, and that it took a higher dose with deeper IgG suppression to deliver the sustained clinical benefit in this patient population. You can see on slide 16, similarly great data on ACR50 and ACR70. You start to run into N issues when you get to ACR70, but we hit a P-value on ACR50 as well. 80% of patients on 600 milligrams had, I think, a nominal P-value if stats want to work, 80% on ACR50 had an ACR50 response at week 28 versus 56% on placebo. Again, nice separation without a nominal P-value on ACR70 at week 28.
Consistent data across depth of response. I really like slide 17, in that you can just see over time that these patients are just It looks like they're significantly benefiting. This is the cohort of patients who were on 600 for the full period, and you can see already some meaningful ACR50 and ACR70 responses as early as week four. Those responses really continue to get better and are well-preserved through the end of the study, even though after week 16, there starts to be a, quote-unquote, "placebo effect," where some of these patients were Where the patients thought they might have been taken off drug at that point. This data looks great, and in my opinion, supports a clinically meaningful profile for these patients that is pretty exciting.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
